Physician

Jehanzeb Riaz, MD

According to 2025 Medicare claims, Jehanzeb Riaz, MD (NPI: 1205130218) practices hematology/oncology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER AND BLOOD SPECIALISTS, LLC (NPI: 1831485267; TIN: 20-2001573) and primary practice location at 74137-4215. Riaz is affiliated with the Lifecare ACO LLC (ACO ID: A3644), Sound Physicians Long Term Care Management, LLC (ACO ID: A5220), Saint Francis Accountable Health Alliance LLC (ACO ID: A5372), CVS ACO (ACO ID: A5407), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Riaz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 479 traditional Medicare patients, billed 119,612 HCPCS/CPT codes, and received $1,739,611 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,495 prescription claims across 390 beneficiaries totaling $8,149,288 in drug costs, led by Xtandi (Enzalutamide). 2021 DME data shows 58 claims. Open Payments data shows 178 records totaling $3,680. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $59,875 to $1,739,611. Similarly, Part D prescription costs have moved sharply higher in recent years, from $57,438 to $8,149,288. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $759 to $2,897.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	485	667	$59,875
2016	427	652	$51,867
2017	507	1,946	$140,336
2018	438	2,054	$126,446
2019	464	1,959	$114,032
2020	399	1,763	$108,857
2021	404	1,010	$71,625
2022	426	1,368	$104,994
2023	456	4,555	$109,320
2024	479	119,612	$1,739,611

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	48	93	$57,438
2016	56	140	$26,328
2017	159	771	$567,003
2018	200	1,443	$1,200,483
2019	233	1,521	$1,577,112
2020	225	1,819	$3,887,326
2021	261	1,510	$2,715,524
2022	224	1,289	$1,975,368
2023	290	1,490	$2,158,228
2024	390	2,495	$8,149,288

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	79	$16,303
2018	25	186	$22,262
2019	43	148	$16,620
2020	N/R	131	$7,585
2021	N/R	58	$4,718
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	150	698	$89
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	76	76	$78
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	224	360	$62
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	72	116	$59
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	77	140	$42

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	106	3,180	$1,485,961
Inlyta	Axitinib	32	960	$661,480
Procrit	Epoetin Alfa	158	4,398	$647,331
Kisqali	Ribociclib Succinate	34	938	$574,657
Lupron Depot	Leuprolide Acetate	70	7,736	$532,823

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	178	$3,680	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jehanzeb Riaz, MD?

Tedicare shows public-source Medicare data for Jehanzeb Riaz, MD (NPI 1205130218), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jehanzeb Riaz, MD have ACO affiliation data?

Jehanzeb Riaz, MD is shown with ACO affiliation data for Lifecare ACO LLC (MSSP, ACO ID A3644), Sound Physicians Long Term Care Management, LLC (MSSP, ACO ID A5220), Saint Francis Accountable Health Alliance LLC (MSSP, ACO ID A5372), CVS ACO (MSSP, ACO ID A5407), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Jehanzeb Riaz, MD?

Jehanzeb Riaz, MD is linked to OKLAHOMA CANCER AND BLOOD SPECIALISTS, LLC (billing NPI 1831485267) in the available physician profile data.

Does Jehanzeb Riaz, MD have Open Payments data?

Jehanzeb Riaz, MD has 178 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.